Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia

Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, Behm FG, Pui CH, Downing JR, Gilliland DG, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75–87.

NOTES

Ferrando, Adolfo ANeuberg, Donna SStaunton, JaneLoh, Mignon LHuard, ChristineRaimondi, Susana CBehm, Fred GPui, Ching HonDowning, James RGilliland, D GaryLander, Eric SGolub, Todd RLook, A ThomasengCA 21765/CA/NCI NIH HHS/CA 68484/CA/NCI NIH HHS/Research Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.Cancer Cell. 2002 Feb;1(1):75-87. doi: 10.1016/s1535-6108(02)00018-1.

Abstract

Human T cell leukemias can arise from oncogenes activated by specific chromosomal translocations involving the T cell receptor genes. Here we show that five different T cell oncogenes (HOX11, TAL1, LYL1, LMO1, and LMO2) are often aberrantly expressed in the absence of chromosomal abnormalities. Using oligonucleotide microarrays, we identified several gene expression signatures that were indicative of leukemic arrest at specific stages of normal thymocyte development: LYL1+ signature (pro-T), HOX11+ (early cortical thymocyte), and TAL1+ (late cortical thymocyte). Hierarchical clustering analysis of gene expression signatures grouped samples according to their shared oncogenic pathways and identified HOX11L2 activation as a novel event in T cell leukemogenesis. These findings have clinical importance, since HOX11 activation is significantly associated with a favorable prognosis, while expression of TAL1, LYL1, or, surprisingly, HOX11L2 confers a much worse response to treatment. Our results illustrate the power of gene expression profiles to elucidate transformation pathways relevant to human leukemia.
Last updated on 02/17/2021